What does the safety evidence say about systemic absorption and cancer risk from topical estrogen?
Topical estrogen has been studied for decades now, and the safety picture is consistent. When you use estrogen on the skin in low doses, it acts locally rather than circulating through the bloodstream. Here at Alloy, this is a big part of why we use estriol in our M4 skincare line. Estriol is a very gentle estrogen that works well on skin but has very weak effects on breast and uterine tissue.
In the interview with Dr. Ellen Gendler and Dr. Corinne Menn, they talk about this directly. When researchers test blood levels in women using topical estriol or even low dose vaginal estradiol, systemic levels are either unchanged or almost imperceptible, and they drop even further as the skin becomes healthier and thicker. Dr. Menn has also cared for breast cancer survivors on aromatase inhibitors and notes that even for them, the small early rise in serum estrogen seen with vaginal products goes right back to baseline quickly once the tissue heals.
The same theme shows up in our written resources. The science page for M4 highlights that topical estriol does not increase systemic estrogen levels and hasn’t been shown to cause hormonal side effects. And in our 2025 clinical testing of the M4 Eye Cream, estrogen levels in the body stayed unchanged after eight weeks of daily use.
If you want to hear Dr. Gendler explain the research and safety data in her own words, this chapter of our YouTube conversation is a good place to start:Research and Safety of Topical Estrogen
Taken together, the evidence supports that topical estriol used on the face or around the eyes stays local and does not raise breast cancer risk.
This answer was created using the following resources:






















